Presentation ACC 2025 Extended Anticoagulant Treatment With A Reduced Versus Full Dose Apixaban In Patients With Cancer-associated Venous Thromboembolism: The API-CAT Study Presenter: Isabelle Mahé March 29, 2025
News Conference News ACC 2025 Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT Caitlin E. Cox March 29, 2025
News Opinion Editor's Corner ACC 2025 What’s Going to Be Hot at ACC 2025? Michael O'Riordan March 26, 2025
News Conference News ACC 2021 SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal L.A. McKeown May 16, 2021